Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.51 USD | -0.18% | -0.25% | +8.47% |
05-16 | Axonics Implant Approved in Australia to Treat Overactive Bladders | MT |
05-16 | Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.47% | 3.45B | |
+11.69% | 128B | |
-8.89% | 11.26B | |
+3.31% | 9.28B | |
+34.88% | 5.42B | |
-22.65% | 4.8B | |
-9.77% | 2.8B | |
-12.15% | 2.1B | |
-11.96% | 1.98B | |
-27.62% | 1.71B |
- Stock Market
- Equities
- AXNX Stock
- News Axonics, Inc.
- KeyBanc Initiates Axonics at Overweight With $70 Price Target, Confident in Ability to Meet or Exceed Consensus Growth Views